| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.6 | -0.5 |
| EPS (diluted, $ a share) | $-0.06 | $-0.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: HEPA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Hepion Pharmaceuticals, Inc.: key numbers
- Share price
- $0.0903Close, Nov 16
- Market cap
- $11.3M
- Shares outstanding
- 125.07MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Hepion Pharmaceuticals, Inc.
All →Hepion Pharmaceuticals Signs $4.38M M&A Deal with Gravitas Life Sciences, LLC
Hepion Pharmaceuticals completed the acquisition of all issued and outstanding membership interests of Gravitas Life Sciences, LLC from Gravitas Collective Corp. The total consideration consisted of $2.0 million in cash, 25,000,000 shares of common stock valued at $2.25 million, and an additional $135,000 payment. The transaction is classified as a related party transaction as several Hepion directors are also officers of Gravitas Life Sciences.
- Value
- $4.38M
- Counterparty
- Gravitas Life Sciences, LLC
Hepion Pharmaceuticals Insider Danina Fisher Buys $10K of Stock
Danina Fisher bought 200,000 shares of Hepion Pharmaceuticals, Inc. at $0.05 a share, worth $10K in total on Sep 29, 2026. Shares held after the trade: 200,000.
- Value
- $10K
- Shares
- 200,000
- Price
- $0.0500
- Trade date
- Sep 29, 2026
Hepion Pharmaceuticals Other 8-K Filing
Hepion Pharmaceuticals filed a Certificate of Amendment to its Certificate of Incorporation to increase the authorized number of shares of common stock to 750,000,000. The amendment became effective upon filing on October 1, 2026. This action increases the company's capacity for future share issuances but does not represent an active capital raise in this filing.